{"id":"basal-insulin-analog","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Basal insulin analogs are long-acting insulin formulations designed to provide steady, background insulin coverage throughout the day and night, mimicking the basal insulin secretion of a healthy pancreas. They bind to insulin receptors on muscle, fat, and liver cells, facilitating glucose uptake and storage while suppressing hepatic glucose production. This helps maintain stable blood glucose levels between meals and overnight in patients with diabetes.","oneSentence":"Basal insulin analogs mimic the body's natural background insulin secretion by binding to insulin receptors and promoting glucose uptake into cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:00.721Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07242664","phase":"PHASE1","title":"Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State","status":"RECRUITING","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2025-10-13","conditions":"Type 1 Diabetes Mellitis","enrollment":12},{"nctId":"NCT05614089","phase":"PHASE4","title":"Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings","status":"COMPLETED","sponsor":"Jing Luo","startDate":"2023-03-15","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes","enrollment":400},{"nctId":"NCT04760626","phase":"PHASE3","title":"A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-01","conditions":"Diabetes Mellitus, Type 2","enrollment":1085},{"nctId":"NCT04974528","phase":"PHASE3","title":"Afrezza® INHALE-1 Study in Pediatrics","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2021-09-29","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":319},{"nctId":"NCT06855615","phase":"PHASE4","title":"Comparison of Thrice-Daily Premixed Human Insulin with Basal-Bolus Therapy Among Patients with Poorly Controlled Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Hospital Sultanah Aminah Johor Bahru","startDate":"2020-10-01","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":44},{"nctId":"NCT05904743","phase":"PHASE4","title":"INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2023-07-07","conditions":"Diabetes Mellitus, Type 1","enrollment":141},{"nctId":"NCT04849845","phase":"PHASE4","title":"Afrezza® Dosing Optimization Study","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2021-04-09","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":20},{"nctId":"NCT00357890","phase":"NA","title":"Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2005-12","conditions":"Diabetes Mellitus, Insulin-Dependent","enrollment":12},{"nctId":"NCT05767255","phase":"PHASE3","title":"Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue","status":"UNKNOWN","sponsor":"Hospital Universitario San Ignacio","startDate":"2022-12-01","conditions":"Diabetes Mellitus, Type 2 Treated With Insulin","enrollment":66},{"nctId":"NCT03557892","phase":"NA","title":"Sensor-augmented Pump Versus Multiple Daily Injections With Degludec as Basal Insulin for Insulin Therapy in Type 1 Diabetes","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2018-04-01","conditions":"Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT03406000","phase":"PHASE4","title":"Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-01-22","conditions":"Type I Diabetes Mellitus","enrollment":170},{"nctId":"NCT03336528","phase":"PHASE4","title":"Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-01-02","conditions":"Type 2 Diabetes","enrollment":180},{"nctId":"NCT02688933","phase":"PHASE4","title":"A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-05","conditions":"Type 1 Diabetes Mellitus","enrollment":638},{"nctId":"NCT01499082","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-12","conditions":"Type 2 Diabetes Mellitus","enrollment":807},{"nctId":"NCT04834362","phase":"PHASE4","title":"Insulin for Hyperglycemia in Stroke Trial","status":"COMPLETED","sponsor":"National Institute of Neurosciences and Hospital, Dhaka","startDate":"2021-04-05","conditions":"Hyperglycemia, Stroke, Acute","enrollment":452},{"nctId":"NCT04323462","phase":"PHASE4","title":"Intensive Glycemic Control For Diabetic Foot Ulcer Healing","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2021-10-01","conditions":"Diabetic Foot Ulcer","enrollment":326},{"nctId":"NCT03430284","phase":"PHASE4","title":"Multifactorial Intervention on Diabetes (MIDiab Study)","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2018-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":6300},{"nctId":"NCT03338010","phase":"PHASE3","title":"A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-03-22","conditions":"Type 2 Diabetes","enrollment":536},{"nctId":"NCT03338023","phase":"PHASE3","title":"A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-03-23","conditions":"Type 1 Diabetes","enrollment":272},{"nctId":"NCT03819790","phase":"PHASE4","title":"The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians","status":"COMPLETED","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2018-10-02","conditions":"Diabetes Mellitus, Type 2","enrollment":119},{"nctId":"NCT04726631","phase":"NA","title":"Insulin in Treatment of Diabetes Mellitus With Pregnancy","status":"COMPLETED","sponsor":"Assiut University","startDate":"2015-01-01","conditions":"Diabetes","enrollment":110},{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258},{"nctId":"NCT03018938","phase":"PHASE4","title":"A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-02-06","conditions":"Type 2 Diabetes Mellitus","enrollment":814},{"nctId":"NCT01352663","phase":"PHASE3","title":"Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients","status":"WITHDRAWN","sponsor":"Wockhardt","startDate":"","conditions":"Type I Diabetes","enrollment":""},{"nctId":"NCT02987751","phase":"PHASE4","title":"A Study on Comparison of Glargine Plus Glulisine With Premixed Insulin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals","startDate":"2016-12-29","conditions":"Type2 Diabetes","enrollment":200},{"nctId":"NCT02455076","phase":"PHASE4","title":"Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-09","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT02490085","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 24 Hours in Adults With Type 2 Diabetes Under Intensive Insulin Therapy","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2015-10","conditions":"Type 2 Diabetes","enrollment":15},{"nctId":"NCT01774565","phase":"NA","title":"Closed-loop Insulin Delivery in the General Ward","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2016-08","conditions":"Diabetes Mellitus","enrollment":43},{"nctId":"NCT01792830","phase":"PHASE3","title":"Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-10","conditions":"Poor Glycemic Control","enrollment":175},{"nctId":"NCT02059174","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-10","conditions":"Type 1 Diabetes Mellitus","enrollment":76},{"nctId":"NCT02706119","phase":"PHASE4","title":"Insulin in Total Parenteral Nutrition","status":"COMPLETED","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2016-07-01","conditions":"Diabetes Mellitus","enrollment":163},{"nctId":"NCT03349489","phase":"NA","title":"Insulin-based Strategies to Prevent Hypoglycemia During Exercise","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2018-05-18","conditions":"Type 1 Diabetes Mellitus","enrollment":20},{"nctId":"NCT03463564","phase":"PHASE4","title":"Insulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic Control in Type 1 Diabetic Patients","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2016-01","conditions":"Type 1 Diabetes Mellitus","enrollment":150},{"nctId":"NCT01182493","phase":"NA","title":"OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2010-12","conditions":"Diabetes Mellitus, Type 2","enrollment":331},{"nctId":"NCT02490098","phase":"PHASE2","title":"Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2018-01","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT02302716","phase":"PHASE3","title":"A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-12","conditions":"Diabetes Mellitus, Type 2","enrollment":493},{"nctId":"NCT02767596","phase":"PHASE4","title":"Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog","status":"TERMINATED","sponsor":"Laniado Hospital","startDate":"2016-07-12","conditions":"Diabetes Mellitus Type 2","enrollment":2},{"nctId":"NCT00184600","phase":"PHASE3","title":"Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":708},{"nctId":"NCT01617434","phase":"PHASE3","title":"The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":451},{"nctId":"NCT01427920","phase":"PHASE4","title":"Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":348},{"nctId":"NCT01006291","phase":"PHASE3","title":"Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":687},{"nctId":"NCT01707134","phase":"PHASE3","title":"Safety and Efficacy of Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1997-09","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":753},{"nctId":"NCT00652288","phase":"PHASE1","title":"Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs","status":"COMPLETED","sponsor":"Yale University","startDate":"2007-04","conditions":"Diabetes Mellitus, Type I","enrollment":36},{"nctId":"NCT02419859","phase":"NA","title":"A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"CeQur Corporation","startDate":"2015-02","conditions":"Type 2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT01421459","phase":"PHASE3","title":"A Study in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-09","conditions":"Diabetes Mellitus, Type 2","enrollment":759},{"nctId":"NCT02278913","phase":"PHASE4","title":"Basal Bolus Versus Human Insulin in Hospitalized Patients With Diabetes in Paraguay","status":"COMPLETED","sponsor":"Universidad Nacional de Asunción","startDate":"2009-04","conditions":"Hyperglycemia, Diabetes","enrollment":134},{"nctId":"NCT00308308","phase":"PHASE3","title":"Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2006-02","conditions":"Diabetes, Type I","enrollment":589},{"nctId":"NCT01421147","phase":"PHASE3","title":"A Study in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-08","conditions":"Diabetes Mellitus, Type 1","enrollment":536},{"nctId":"NCT00883558","phase":"PHASE2","title":"Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2009-05","conditions":"Diabetes Mellitus, Type 1","enrollment":48},{"nctId":"NCT00862875","phase":"PHASE4","title":"Levemir-Body Composition and Energy Metabolism","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2009-03","conditions":"Type 2 Diabetes","enrollment":42},{"nctId":"NCT01828970","phase":"PHASE4","title":"Pilot Study of Glycemic Control in Diabetic Hemodialyzed Patients","status":"COMPLETED","sponsor":"Centre Europeen d'Etude du Diabete","startDate":"2010-01","conditions":"Diabetes Mellitus","enrollment":38},{"nctId":"NCT01398670","phase":"PHASE3","title":"Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics","status":"WITHDRAWN","sponsor":"Wockhardt","startDate":"2012-02","conditions":"Type I Diabetes","enrollment":""},{"nctId":"NCT01136746","phase":"PHASE3","title":"Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2011-03","conditions":"Hyperglycemia","enrollment":16},{"nctId":"NCT01271517","phase":"PHASE4","title":"Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2005-09","conditions":"Diabetes Mellitus Type 1","enrollment":120},{"nctId":"NCT00487240","phase":"PHASE3","title":"Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-06","conditions":"Diabetes Mellitus, Type 1","enrollment":387},{"nctId":"NCT01088451","phase":"NA","title":"Joint Application of Human Insulin and Rapid Insulin Analogue in Control of Postprandial Glycemia","status":"UNKNOWN","sponsor":"University Hospital Hradec Kralove","startDate":"2009-12","conditions":"Diabetes Mellitus, Type 1","enrollment":20},{"nctId":"NCT00494013","phase":"PHASE3","title":"Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-08","conditions":"Diabetes Mellitus Type 2","enrollment":442},{"nctId":"NCT00747409","phase":"PHASE4","title":"Insulin Effects on Metabolism and Cardiovascular Function in Type 2 Diabetes","status":"UNKNOWN","sponsor":"Munich Municipal Hospital","startDate":"2004-07","conditions":"Type 2 Diabetes Mellitus","enrollment":120},{"nctId":"NCT00732524","phase":"PHASE4","title":"Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA","status":"COMPLETED","sponsor":"Cook County Health","startDate":"2004-09","conditions":"Type 2 Diabetes","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":94,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Basal Insulin Analog","genericName":"Basal Insulin Analog","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Basal insulin analogs mimic the body's natural background insulin secretion by binding to insulin receptors and promoting glucose uptake into cells. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}